Author Title [ Type(Asc)] Year
Filters: Author is Blin, Nicolas  [Clear All Filters]
Journal Article
Doz F, Locatelli F, Baruchel A, Blin N, de Moerloose B, Frappaz D, Dworzak M, Fischer M, Stary J, Fuertig R, et al. Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. Pediatr Blood Cancer. 2019:e27900.
Bouard L, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Duquenne A, Mahe B, Dubruille V, Blin N, Touzeau C, et al. Influence of donor type (sibling vs matched-unrelated donor vs haplo-identical donor) on outcomes after clofarabine-based reduced-intensity conditioning allograft for myeloid malignancies. Biol Blood Marrow Transplant. 2019.
Chevallier P, Berceanu A, Peterlin P, Garnier A, Le Bourgeois A, Imbert B-M, Daguindau E, Mahe B, Dubruille V, Blin N, et al. Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta Oncol. 2020:1-9.
Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Chérel M, Debord C, Le Bris Y, Theisen O, et al. FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia. Cytokine. 2019;120:85-87.
Laurent V, Fronteau C, Antier C, Dupuis P, Tessoulin B, Gastinne T, Mahe B, Blin N, Dubruille V, Lok A, et al. Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. Bone Marrow Transplant. 2020.